康布查茶作为糖尿病患者的抗高血糖剂 - 一个随机控制的试点调查调查
Chagai Mendelson1, Sabrina Sparkes2, Daniel J Merenstein2,3
1Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Frontiers in nutrition
|August 17, 2023
概括
在患有II型糖尿病的成年人中,康布查的消费显著降低了禁食血糖. 这项试点研究表明,kombucha可能是管理血糖水平的有益辅助疗法.
科学领域:
- 代谢健康 代谢健康
- 微生物学 微生物学
- 临床营养学 临床营养学
背景情况:
- 康布查,一种发酵茶,被认为具有潜在的健康益处.
- 动物研究表明,kombucha可能会降低血糖水平.
- 二型糖尿病 (T2DM) 的管理需要有效的干预措施.
研究的目的:
- 评估kombucha在患有T2DM的成年人的抗高血糖作用.
- 评估kombucha对禁食血糖水平的影响.
- 探索与康布查消费相关的二次健康结果.
主要方法:
- 未来的,随机的,双盲的,交叉试点研究.
- 12名患有T2DM的成年参与者在4周内食用了康布查或安慰剂,随后进行了洗和替代治疗.
- 在基线,第1周和第4周测量禁食血糖;通过问卷评估二次结果.
主要成果:
- 与基线 (164 mg/dL,p=0.035) 相比,Kombucha消费在4周内显著降低了平均禁食血糖 (116 mg/dL).
- 而安慰剂并没有显著降低空腹血糖 (141 mg/dL vs. 162 mg/dL,p=0.078).
- 康布查微生物群的分析显示,主要的乳酸细菌,酸细菌和酵母 (Dekkera).
结论:
- 这项试点研究表明,康布查的消费与T2DM患者的血糖水平降低有关.
- 尽管样本规模很小,但研究结果支持进一步调查kombucha的抗糖尿病潜力.
- 需要进行更大规模的临床试验来证实这些抗高血糖作用.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: Glinides
184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184
Oral Hypoglycemic Agents: Sulfonylureas
236
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
236


